Nitroxoline: a broad-spectrum biofilm-eradicating agent against pathogenic bacteria

Nitroxoline: a broad-spectrum biofilm-eradicating agent against pathogenic bacteria

ARTICLE IN PRESS International Journal of Antimicrobial Agents ■■ (2016) ■■–■■ Contents lists available at ScienceDirect International Journal of An...

857KB Sizes 2 Downloads 64 Views

ARTICLE IN PRESS International Journal of Antimicrobial Agents ■■ (2016) ■■–■■

Contents lists available at ScienceDirect

International Journal of Antimicrobial Agents j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / i j a n t i m i c a g

1 2 3 4 5 6

Q2 Short Communication

Nitroxoline: a broad-spectrum biofilm-eradicating agent against pathogenic bacteria Q1 Yasmeen Abouelhassan a, Qingping Yang b, Hussain Yousaf a, Minh Thu Nguyen a,

Melanie Rolfe a, Gregory S. Schultz b, Robert W. Huigens III a,*

7

a

8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35

b

Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1600 SW Archer Road, Gainesville, FL 32610, USA Institute of Wound Research, Department of Obstetrics and Gynecology, College of Medicine, University of Florida, Gainesville, FL 32610, USA

A R T I C L E

I N F O

Article history: Received 7 July 2016 Accepted 8 October 2016 Keywords: Nitroxoline Biofilm eradication Antibiotic tolerance Drug discovery Antibiofilm agents

A B S T R A C T

Bacterial biofilms are surface-attached communities of slow-growing or non-replicating bacteria tolerant to conventional antibiotic therapies. Although biofilms are known to occur in ca. 80% of all bacterial infections, no therapeutic agent has been developed to eradicate bacteria housed within biofilms. We have discovered that nitroxoline, an antibacterial agent used to treat urinary tract infections, displays broad-spectrum biofilm-eradicating activities against major human pathogens, including drugresistant Staphylococcus aureus and Acinetobacter baumannii strains. In this study, the effectiveness of nitroxoline to eradicate biofilms was determined using an in vitro [minimum biofilm eradication concentration (MBEC) = 46.9 μM against A. baumannii] and ex vivo porcine skin model (2–3 log reduction in viable biofilm cells). Nitroxoline was also found to eradicate methicillin-resistant S. aureus (MRSA) persister cells in non-biofilm (stationary) cultures, whereas vancomycin and daptomycin were found to be inactive. These findings could lead to effective, nitroxoline-based therapies for biofilm-associated infections. © 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58

1. Introduction

2. Materials and methods

Free-floating planktonic bacteria use a signalling process known as quorum sensing to co-ordinate virulent behaviours, including the formation of surface-attached biofilms [1]. Bacteria encased within a biofilm lead a slow- or non-growing (dormant) existence and have contrastingly different gene expression profiles compared with their planktonic counterparts [2–4]. As a result, biofilms are highly tolerant to conventional antibiotics and are the underlying cause of many recurring and chronic infections [5]. We have discovered halogenated quinolines and phenazines capable of eradicating biofilms of multiple Gram-positive pathogens [6–10], which led us to nitroxoline, a structurally related antibacterial agent used to treat urinary tract infections [11,12]. Nitroxoline operates through a metal chelation-dependent mechanism and has reported biofilm dispersal activity against Pseudomonas aeruginosa [13]. Here we report our findings of the broad-spectrum biofilm-eradicating activities of nitroxoline against multiple human pathogens. This phenotype is extremely rare as mitomycin C has been the only reported broad-spectrum biofilmeradicating agent that does not target bacterial membranes for destruction [14].

2.1. Bacterial strains Multidrug-resistant (MDR) Acinetobacter baumannii ATCC 1794, A. baumannii ATCC 19606, P. aeruginosa PAO1, methicillin-resistant Staphylococcus aureus (MRSA) ATCC BAA-1707, methicillin-resistant Staphylococcus epidermidis (MRSE) ATCC 35984 and vancomycinresistant Enterococcus faecium (VRE) ATCC 700221 were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Methicillin-resistant S. aureus MRSA-1, MRSA-2 and MRSA-156 and methicillin-resistant S. epidermidis MRSE-1 were obtained as clinical isolates from patients treated at Shands Hospital (Gainesville, FL). UAEC-1 is an Escherichia coli isolate from UAMS Hospital (Fayetteville, AR). 2.2. Minimum inhibitory concentration (MIC) assays MIC assays were performed as previously described to determine antibacterial activities against pathogenic bacteria [6–10,15]. Results from MIC assays were obtained from three independent experiments (Table 1).

59 60 61 62 63

2.3. Minimum biofilm eradication concentration (MBEC) assays

Q3

* Corresponding author. Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1600 SW Archer Road, Gainesville, FL 32610, USA. E-mail address: [email protected]fl.edu (R.W. Huigens III).

Biofilm eradication assays were performed in 96-well plates (polystyrene for MRSA-2 and MRSE-1; polyvinyl chloride for A.

http://dx.doi.org/10.1016/j.ijantimicag.2016.10.017 0924-8579/© 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Please cite this article in press as: Yasmeen Abouelhassan, et al., Nitroxoline: a broad-spectrum biofilm-eradicating agent against pathogenic bacteria, International Journal of Antimicrobial Agents (2016), doi: 10.1016/j.ijantimicag.2016.10.017

64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90

ARTICLE IN PRESS Y. Abouelhassan et al. / International Journal of Antimicrobial Agents ■■ (2016) ■■–■■

2

91 92 93

Table 1 Summary of antibacterial and biofilm eradication assays performed in 96-well plates and in Calgary Biofilm Devices (CBDs). All values are reported in μM. Strain/isolate

94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114

Acinetobacter baumannii 19606b A. baumannii 1794b UAEC-1 PAO1 MRSA-1 MRSA-2f MRSA-156 MRSA-BAA-1707 MRSE-1f MRSE 35984 VRE 700221

Colistina

Nitroxoline

Vancomycina

96-well plates (MIC/MBEC)

CBD (MBC/MBEC)

96-well plates (MIC/MBEC)

CBD (MBC/MBEC)

96-well plates (MIC/MBEC)

CBD (MBC/MBEC)

6.25/46.9c 4.69c/62.5 12.5/— 250/1500c 12.5/— 25/188c 12.5/— 9.38c/— 18.8c/125 18.8c/— 125/—

—d 125/46.9c 93.8c/62.5 — 250/188c 250/62.5 750c/125c 250/93.8c — 500/250 125/62.5

0.39/1000 0.39/— 0.39/— 0.78/1500c — — — — — — —

— 375c/375c 11.7c/46.9c — — — — — — — —

— — — — 0.39 0.78/>2000 0.78 0.39 0.59c/>2000 — >100/—

— — — — 15.6e/750c 11.7c/62.5 31.3/750c 23.5c/1500c — — >100/150c

MIC, minimum inhibitory concentration; MBEC, minimum biofilm eradication concentration; MBC, minimum bactericidal concentration. All data were obtained from three independent experiments. a Colistin served as the anti-Gram-negative comparator antibiotic and vancomycin served as the anti-Gram-positive comparator antibiotic in these experiments. b A. baumannii biofilms were grown on polyvinyl chloride plates. c Corresponds to the mid-point of a two-fold range in MIC, MBC or MBEC values. d Indicates not tested. e Corresponds to the mid-point value of a four-fold range in MBC experiments. f MRSA-2 and MRSE-1 biofilms were grown on polystyrene plates.

115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157

baumannii and PAO1) [6] or in Calgary Biofilm Devices (CBDs) [7–10,16]. Biofilm eradication assays involve three phases separated by wash steps, including (i) initial biofilm establishment on well/peg surfaces without test compound; (ii) biofilm treatment with test compound; and (iii) recovery of viable biofilms in fresh medium alone. Both assays were used to demonstrate the biofilm eradication activities of nitroxoline. For polystyrene and polyvinyl chloride 96-well plate biofilm eradication assays, microtitre wells were inoculated with 100 μL of a 1:1000-fold exponential-phase culture [optical density at 600 nm (OD600) of ca. 1.0] and were incubated for 24 h at 37 °C to allow biofilms to establish on the surface of microtitre wells (phase 1). Following biofilm establishment, medium and planktonic cells were removed from microtitre plates and the plates were rinsed with water. Then, 100 μL of two-fold serial dilutions of test compound was added to the microtitre wells in fresh medium and was incubated for 24 h at 37 °C (phase 2). After this time, the contents of the microtitre wells were removed and 100 μL of fresh medium only was added to allow viable biofilms to recover and to disperse planktonic bacteria into the medium resulting in a turbid microtitre well (24-h incubation at 37 °C; phase 3). After this final phase, microtitre plates were examined for visible bacterial growth (turbidity) and the MBEC was recorded as the lowest concentration at which no turbidity could be observed (due to eradicated biofilms). For MRSA-2 and MRSE-1 biofilm eradication assays, 100 μL of a 1% gelatin (aqueous) solution was used to pre-treat polystyrene plates for a minimum of 1 h to enhance S. aureus and S. epidermidis biofilm formation, as previously reported [17,18]. Biofilm eradication assays involving CBDs (Innovotech Inc., Edmonton, AB, Canada) (Supplementary Fig. S1) were performed in an analogous manner to the previous microtitre plate assay; however, CBDs allow biofilms to be established and treated on pegs suspended from 96-well plate lids. We have previously reported these assay conditions [7–10,16]. CBD experiments with A. baumannii 1794, UAEC-1, all MRSA strains and MRSE 35984 were carried out on hydroxyapatite-coated P&G devices, whilst experiments with VRE 700221 were performed on non-coated P&G CBDs. 2.4. Ex vivo porcine skin biofilm model Biofilms were formed on porcine skin explants as previously described [17,18] (Supplementary Fig. S2) with slight modifications.

Briefly, porcine skin explants were inoculated with 20 μL of bacterial culture (OD600 = 0.2–0.4) and were incubated on agar for 48 h at 37 °C to establish biofilms on porcine skin explants. Following biofilm establishment, porcine skin explants were treated with test compound in phosphate-buffered saline (PBS) at 400 μM for 72 h (at 37 °C). After this time, porcine skin explants were rinsed with PBS to remove planktonic cells and the remaining biofilm cells were removed via sonication from the porcine explants. Subsequent colony counts were performed to determine relative biofilm viabilities between treated and untreated (vehicle-only) samples.

158 159 160 161 162 163 164 165 166 167 168

2.5. MRSA-2 stationary cell kill kinetics MRSA-2 stationary killing was performed as previously described [8]. Briefly, an MRSA-2 overnight culture was diluted in fresh medium and was allowed to grow for 4 h to reach stationary phase. Test compound was then added to stationary cultures and aliquots were removed to perform colony counts to determine CFU/mL (viable bacteria) at pre-determined time points.

169 170 171 172 173 174 175 176 177

2.6. Minimum biofilm inhibitory concentration (MBIC) determination In PVC 96-well plates, two-fold serial dilutions of test compounds were added in LB medium. Then, 1:1000-fold exponentialphase culture (OD600 of ca. 0.8) in LB was added to each well and was allowed to incubate at 37 °C for 24 h. After this time, the contents from the 96-well plates were removed and the wells were rinsed with water, followed by the addition of 120 μL of crystal violet to stain the biofilms (0.1% for A. baumannii and 1% for PAO1; 10min incubation at room temperature). The plates were then rinsed and 120 μL of ethanol was added to dissolve the crystal violetstained biofilms. Minimum concentrations required to inhibit 80% of biofilm formation (MBIC80) were determined (OD540) by comparing compound-treated versus untreated wells and the resulting data were used to generate dose–response curves using GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA). Note: these experiments were performed to determine whether the antibiofilm activities of nitroxoline were dependent on or independent of their antibacterial activities (Supplementary Table S1; Supplementary Fig. S3).

Please cite this article in press as: Yasmeen Abouelhassan, et al., Nitroxoline: a broad-spectrum biofilm-eradicating agent against pathogenic bacteria, International Journal of Antimicrobial Agents (2016), doi: 10.1016/j.ijantimicag.2016.10.017

178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198

ARTICLE IN PRESS Y. Abouelhassan et al. / International Journal of Antimicrobial Agents ■■ (2016) ■■–■■

199 200

3

Fig. 1. (A) Acinetobacter baumannii 19606 biofilm eradication using 96-well plates and (B) multidrug-resistant (MDR) A. baumannii 1794 biofilm eradication using the Calgary Biofilm Device (CBD). Concentration ranges from 2 to 2000 μM for nitroxoline and colistin. MBEC, minimum biofilm eradication concentration; DMSO, dimethyl sulphoxide.

201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246

3. Results Nitroxoline demonstrated broad-spectrum antibacterial activities (Table 1) against A. baumannii (MIC = 4.69–6.25 μM; 0.9–1.2 mg/L), E. coli UAEC-1 (MIC = 12.5 μM; 2.4 mg/L), MRSA strains (MIC = 9.38–25 μM; 1.8–4.8 mg/L) and MRSE-1 (MIC = 18.8 μM; 3.6 mg/L); however, nitroxoline displayed weak antibacterial activities against VRE 700221 (MIC = 125 μM; 24 mg/L) and PAO1 (MIC = 250 μM; 48 mg/L). Encouraged by the broad-spectrum antibacterial activities of nitroxoline against planktonic bacteria, we then moved to bacterial biofilms to determine eradication activities. The biofilm eradication activities of nitroxoline were initially investigated in vitro by treating bacterial biofilms established on the bottom of 96well plates and with the CBD. The CBD apparatus allows for the simultaneous determination of planktonic and biofilm cell eradication in a single assay, resulting in a more accurate comparison between the planktonic [i.e. minimum bactericidal concentration (MBC)] and biofilm (i.e. MBEC) activities. Nitroxoline was found to have broad-spectrum biofilm eradication activities in both in vitro assays (Table 1). Interestingly, A. baumannii biofilms proved to be most sensitive to the eradication activities of nitroxoline (MBEC = 46.9–62.5 μM; 8.9–11.9 mg/L) (Table 1; Fig. 1). In 96-well plates and CBDs, nitroxoline was found to be >20-fold more potent than colistin against A. baumannii biofilms. In addition, nitroxoline demonstrated biofilm eradication activities in 96-well plate and CBD assays against MRSA strains (MBEC = 62.5–188 μM) (Table 1), MRSE-1 and MRSE 35984 with MBECs of 125 μM and 250 μM, respectively (Table 1). Nitroxoline outperformed vancomycin in staphylococcal biofilm eradication whilst demonstrating similar planktonic and biofilm cell eradication activities (MBC/MBEC values; Table 1). In these assays, vancomycin was more selective in killing planktonic cells compared with biofilm cells, demonstrating much more potent MBC values than MBEC values, typical of conventional antibiotics (growth inhibitors). Nitroxoline also proved to effectively eradicate E. coli UAEC-1 (MBEC = 62.5 μM) and VRE 700221 (MBEC = 62.5 μM) biofilms in CBD assays whilst demonstrating significantly less potent biofilm eradication activities against PAO1 (Table 1). After investigating the biofilm eradication activities of nitroxoline in vitro, we moved to a more sophisticated ex vivo (wound) biofilm infection model using porcine skin explants. Since biofilms formed in vivo are different from those formed on plastic in vitro surfaces, we chose the ex vivo porcine biofilm model as a better representative for biofilms grown on tissues. For these experiments, we modified published protocols using our ex vivo model [19,20].

Porcine skin explants were inoculated and were allowed to incubate on agar for 48 h, producing a relatively immature but established bacterial biofilm (ca. 107 CFU/mL biofilm cells) on the porcine skin explants. The infected porcine skin explants were then washed to remove planktonic bacteria and were treated with nitroxoline at 400 μM for 72 h. Similar to in vitro assays, nitroxoline effectively reduced the viability of established A. baumannii, E. coli UAEC-1, MRSA-2 and MRSE 35984 biofilms in the order of 2–3 log reduction (99–99.9% killing) of viable biofilm cells using this ex vivo model (Fig. 2A). In addition, nitroxoline was more effective at killing biofilm cells than colistin against A. baumannii and E. coli biofilms and than vancomycin against MRSA-2 and MRSE 35984 biofilms in these porcine skin experiments. Interestingly, in MIC assays, these bacterial strains proved to be highly sensitive (MIC < 0.78 μM) to these conventional antibiotics (Table 1). Following biofilm eradication studies, kill kinetic experiments were performed against MRSA-2 stationary-phase cultures rich in persister cells with nitroxoline (200 μM; 8× MIC), vancomycin (200 μM; 256 × MIC) and daptomycin (200 μM; 43× MIC). In addition, the membrane-lysing antimicrobial peptide mimic QAC-10 (quaternary ammonium cation-10 [21–24]) was used as a positive control owing to its ability to rapidly eradicate MRSA-2 persister cells in stationary-phase cultures [8]. Nitroxoline demonstrated a slow yet effective ability to eradicate stationary (persister) cells by causing a >4-log reduction (>99.99%) of viable MRSA-2 stationary phase cells after 24 h (Fig. 2B). Front-running MRSA therapies, i.e. daptomycin and vancomycin, were found to be ineffective at eradicating MRSA stationary cells at 200 μM. Despite these high concentrations of daptomycin and vancomycin (i.e. 43× and 256× their corresponding MICs), these antibiotics were unable to eradicate MRSA persisters, illustrating the innate tolerance that persister cells display towards antibiotics. QAC-10 rapidly eradicated MRSA stationary cultures, typical of membrane-lysing agents [21–24].

247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280

4. Discussion Bacterial biofilms are the underlying cause of persistent and recurring infections [2–4]. Unfortunately, our antibiotic arsenal is not poised to effectively treat biofilm-associated infections as these agents were initially discovered as growth inhibitors against rapidly-dividing bacteria [5,8–10]. In addition, pharmaceutical companies have either reduced or eliminated antibacterial discovery programmes [25] despite the need for biofilm-eradicating therapies.

Please cite this article in press as: Yasmeen Abouelhassan, et al., Nitroxoline: a broad-spectrum biofilm-eradicating agent against pathogenic bacteria, International Journal of Antimicrobial Agents (2016), doi: 10.1016/j.ijantimicag.2016.10.017

281 282 283 284 285 286 287 288 289 290

ARTICLE IN PRESS 4

291 292 293 294

Y. Abouelhassan et al. / International Journal of Antimicrobial Agents ■■ (2016) ■■–■■

Fig. 2. (A) Biofilm eradication with nitroxoline (Nitrox), colistin and vancomycin (Vanc) using an ex vivo porcine skin model against Acinetobacter baumannii 1794, methicillinresistant Staphylococcus aureus MRSA-2, methicillin-resistant Staphylococcus epidermidis (MRSE) 35984 and Escherichia coli UAEC-1. All compounds were tested at 400 μM. (B) Kinetics of MRSA-2 stationary cell eradication using nitroxoline, vancomycin, daptomycin and QAC-10. *Corresponds to the lowest detection level of viable stationary cells tested in this experiment. DMSO, dimethyl sulphoxide.

295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316

Nitroxoline was previously reported to demonstrate biofilm dispersion activities against P. aeruginosa [13]; however, our MBEC, MRSA stationary killing, ex vivo biofilm killing and MBIC80:MIC ratios (Supplementary Table S1) against multiple pathogenic bacteria suggest that any antibiofilm activities demonstrated by nitroxoline are likely due to biofilm eradication and not a mechanism independent of its antibacterial activities, such as biofilm attachment and dispersion. These findings are timely as mitomycin C is the only non-membrane-active broad-spectrum biofilm-eradicating agent reported in the literature [14]. During these investigations, nitroxoline outperformed conventional antibiotics (i.e. colistin for A. baumannii and vancomycin for MRSA/MRSE) in biofilm/MRSA stationary cell eradication experiments and in an ex vivo porcine skin infection model, suggesting that nitroxoline may be an effective topical treatment for biofilm-associated skin wounds. The biofilm-related therapeutic applications for nitroxoline-based therapies are numerous (i.e. device-related biofilm infections, wound infections) and could be streamlined as this agent is an approved drug. Importantly, nitroxoline is a structurally simple molecule and could be used as a synthetic template for extensive drug development efforts.

5. Conclusion We have demonstrated that nitroxoline possesses broad-spectrum biofilm eradication activities against several human pathogens, including MDR A. baumannii, E. coli, MRSA, MRSE and VRE. As persister cells lead to high levels of antibiotic tolerance in biofilm infections, finding new agents that operate through novel modes of action that lead to the eradication of persister cells in biofilms is critical, thus our findings are timely. Nitroxoline-based therapies could lead to significant advances in the treatment of persistent biofilmassociated bacterial infections. Funding: This work was funded by the College of Pharmacy and Q4 the Division of Sponsored Research at the University of Florida Q5 (Gainesville, FL) [start-up funds]. Competing interests: None declared. Ethical approval: Not required. Appendix. Supplementary data Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.ijantimicag.2016.10.017.

Please cite this article in press as: Yasmeen Abouelhassan, et al., Nitroxoline: a broad-spectrum biofilm-eradicating agent against pathogenic bacteria, International Journal of Antimicrobial Agents (2016), doi: 10.1016/j.ijantimicag.2016.10.017

317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337

ARTICLE IN PRESS Y. Abouelhassan et al. / International Journal of Antimicrobial Agents ■■ (2016) ■■–■■

338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375

References [14] [1] Camilli A, Bassler BL. Bacterial small-molecule signaling pathways. Science 2006;311:1113–16. [2] Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 2007;5:48–56. [3] Lewis K. Persister cells. Annu Rev Microbiol 2010;64:357–72. [4] Wood TK, Knabel SJ, Kwan BW. Bacterial persister cell formation and dormancy. Appl Environ Microbiol 2013;79:7116–21. [5] Wood TK. Combatting bacterial persister cells. Biotechnol Bioeng 2016; 113:476–83. [6] Abouelhassan Y, Garrison AT, Bai F, Norwood IVVM, Nguyen M, Jin S, et al. A phytochemical–halogenated quinoline combination therapy strategy for the treatment of pathogenic bacteria. ChemMedChem 2015;10:1157–62. [7] Basak A, Abouelhassan Y, Huigens IIIRW. Halogenated quinolines discovered through reductive amination with potent eradication activities against MRSA, MRSE and VRE biofilms. Org Biomol Chem 2015;13:10290–4. [8] Garrison AT, Abouelhassan Y, Kallifidas D, Bai F, Ukhanova M, Mai V, et al. Halogenated phenazines that potently eradicate biofilms, MRSA persister cells in non-biofilm cultures, and Mycobacterium tuberculosis. Angew Chem Int Ed Engl 2015;54:14819–23. [9] Garrison AT, Abouelhassan Y, Norwood IVVM, Kallifidas D, Bai F, Nguyen M, et al. Structure–activity relationships of a diverse class of halogenated phenazines that targets persistent, antibiotic-tolerant bacterial biofilms and Mycobacterium tuberculosis. J Med Chem 2016;59:3808–25. [10] Basak A, Abouelhassan Y, Norwood IVVM, Bai F, Nguyen M, Jin S, et al. Synthetically tuning the 2-position of halogenated quinolines: optimizing antibacterial and biofilm eradication activities via alkylation and reductive amination pathways. Chem Eur J 2016;22:9181–9. [11] Wagenlehner FME, Münch F, Pilatz A, Bärmann B, Weidner W, Wagenlehner CM, et al. Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers. Antimicrob Agents Chemother 2014;58:713–21. [12] Pelletier C, Prognon P, Bourlioux P. Roles of divalent cations and pH in mechanism of action of nitroxoline against Escherichia coli strains. Antimicrob Agents Chemother 1995;39:707–13. [13] Sobke A, Klinger M, Hermann B, Sachse S, Nietzsche S, Makarewicz O, et al. The urinary antibiotic 5-nitro-8-hydroxyquinoline (nitroxoline) reduces the

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

5

formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc. Antimicrob Agents Chemother 2012;56:6021–5. Kwan BW, Chowdhury N, Wook K. Combatting bacterial infections by killing persister cells with mitomycin C. Environ Microbiol 2015;17:4406–14. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Wayne (PA): CLSI; 2009 Document M07-A8. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999;37:1771–6. Garrison AT, Bai F, Abouelhassan Y, Paciaroni NG, Jin S, Huigens IIIRW. Bromophenazine derivatives with potent inhibition, dispersion and eradication activities against Staphylococcus aureus biofilms. RCS Adv 2015;5:1120–4. Abouelhassan Y, Garrison AT, Burch GM, Wong W, Norwood IVVM, Huigens IIIRW. Discovery of quinoline small molecules with potent dispersal activity against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis biofilms using a scaffold hopping strategy. Bioorg Med Chem Lett 2016;24: 5076–80. Phillips PL, Yang Q, Sampson E, Schultz G. Effects of antimicrobial agents on an in vitro biofilm model of skin wounds. Adv Wound Care (New Rochelle) 2010;1:299–304. Yang Q, Phillips PL, Sampson EM, Progulske-Fox A, Jin S, Antonelli P, et al. Development of a novel ex vivo porcine skin explant model for the assessment of mature bacterial biofilms. Wound Repair Regen 2013;21:704–14. Jennings MC, Ator LE, Paniak TJ, Minibole KPC, Wuest WM. Biofilm eradicating properties of quaternary ammonium amphiphiles: simple mimics of antimicrobial peptides. Chembiochem 2014;15:2211–15. Paniak TJ, Jennings MC, Shanahan PC, Joyce MD, Santiago CN, Wuest WM, et al. The antimicrobial activity of mono-, bis-, tris-, and tetracationic amphiphiles derived from simple polyamine platforms. Bioorg Med Chem Lett 2014;24:5824–8. Jennings MC, Buttaro BA, Minbiole KPC, Wuest WM. Bioorganic investigation of multicationic antimicrobials to combat QAC-resistant Staphylococcus aureus. ACS Infect Dis 2015;1:304–9. Forman ME, Jennings MC, Wuest WM, Minbiole KPC. Building a better quaternary ammonium compound (QAC): branched tetracationic antiseptic amphiphiles. ChemMedChem 2016;11:1401–5. Harbarth S, Theuretzbacher U, Hackett J. Antibiotic research and development: business as usual? J Antimicrob Chemother 2015;70:1604–7.

Please cite this article in press as: Yasmeen Abouelhassan, et al., Nitroxoline: a broad-spectrum biofilm-eradicating agent against pathogenic bacteria, International Journal of Antimicrobial Agents (2016), doi: 10.1016/j.ijantimicag.2016.10.017

376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414